摘要目的：探讨孕早期合并亚临床甲状腺功能减退（亚甲减）及其甲状腺过氧化物酶抗体（TPOAb）阳性孕妇治疗与否对围产结局的影响。方法2013年1月1日至2014年6月30日郑州市妇幼保健院分娩孕妇15000例，其中孕早期合并亚甲减孕妇2042例，其诊断标准为促甲状腺素（TSH）水平5.22~10.00 mU/L、血清游离甲状腺素（FT4）水平12.91~22.35 pmol/L；TPOAb水平≥34 U/L为阳性。2042例亚甲减孕妇根据是否接受左旋甲状腺素片治疗分为亚甲减治疗组（1236例）和亚甲减未治疗组（806例）；同时根据2042例亚甲减孕妇TPOAb检测结果是否阳性及是否接受左旋甲状腺素片治疗，分为TPOAb（+）治疗组（1021例）、TPOAb（+）未治疗组（201例），TPOAb（-）治疗组（215例）、TPOAb（-）未治疗组（605例）。选取同期甲状腺功能正常孕妇2000例作为对照组。对各组孕妇围产结局进行分析。结果（1）孕早期合并亚甲减的发生率为13.61%（2042/15000）；治疗率为60.53%（1236/2042），未治疗率为39.47%（806/2042）。（2）亚甲减未治疗组孕妇流产（5.71%，46/806）、早产（6.20%，50/806）、妊娠期高血压疾病（13.90%，112/806）、妊娠期糖尿病[GDM；6.58%（53/806）]、胎儿生长受限[FGR；12.28%（99/806）]及出生低体质量儿（10.17%，82/806）的发生率均高于亚甲减治疗组分别为3.96%（49/1236）、4.21%（52/1236）、10.76%（133/1236）、4.13%（51/1236）、8.90%（110/1236）、7.52%（93/1236）及对照组[分别为3.60%（72/2000）、4.00%（80/2000）、10.70%（214/2000）、3.80%（76/2000）、9.60%（192/2000）、7.50%（150/2000）]，分别比较，差异均有统计学意义（P<0.05）；胎盘早剥、孕妇贫血、胎儿窘迫的发生率在亚甲减治疗组、亚甲减未治疗组及对照组之间分别比较，差异均无统计学意义（P>0.05）。（3）TPOAb（+）未治疗组孕妇流产（11.44%，23/201）、早产（12.44%，25/201）、妊娠期高血压疾病（22.89%，46/201）、GDM（8.46%，17/201）、FGR（19.90%，40/201）及出生低体质量儿（16.42%，33/201）的发生率均高于TPOAb（+）治疗组[分别为4.02%（41/1021）、4.21%（43/1021）、10.77%（110/1021）、4.11%（42/1021）、8.72%（89/1021）、7.35%（75/1021）]和对照组，分别比较，差异均有统计学意义（P<0.05）；TPOAb（+）治疗组孕妇不良围产结局发生率虽高于对照组，但差异均无统计学意义（P>0.05）。（4）TPOAb（-）治疗组孕妇流产（3.72%，8/215）、早产（4.19%，9/215）、妊娠期高血压疾病（10.70%，23/215）、GDM（4.19%，9/215）、FGR（9.77%，21/215）及出生低体质量儿（8.37%，18/215）的发生率分别与TPOAb（-）未治疗组[分别为3.80%（23/605）、4.13%（25/605）、10.91%（66/605）、5.95%（36/605）、9.75%（59/605）、8.10%（49/605）]及对照组比较，差异均无统计学意义（P>0.05）。结论（1）孕早期合并亚甲减可增加流产、早产、妊娠期高血压疾病、GDM、FGR及出生低体质量儿的发生率；（2）左旋甲状腺素片治疗可有效降低孕早期合并亚甲减孕妇及其中TPOAb（+）孕妇的妊娠并发症及合并症的发生率。

abstractsObjective To investigate if women with subclinical hypothyroidism (SCH), positive thyroid gland peroxidase antibody(TPOAb) in early pregnancy accepted treatment or not had effect on perinatal outcomes. Methods 15 000 pregnant women who delivered in Women and Infants Hospital of Zhengzhou from January 1, 2013 to June 30, 2014 were recruited retrospectively. Among them, 2 042 women had SCH in early pregnancy. The diagnostic standard of SCH was serum free thyroxine (FT4) between 12.91-22.35 pmol/L and TSH level between 5.22-10.00 mU/L. TPOAb level ≥34 U/L was defined as positive result. The 2 042 patients with SCH were divided into the treated group (1 236 cases) and the untreated group (806 cases), according to whether or not women accepted the levothyroxine treatment. Meanwhile, the 2 042 patients with SCH were divided into the TPOAb (+) treated group (1 021 cases), the TPOAb (+) untreated group (201 cases), the TPOAb (-) treated group (215 cases) and the TPOAb (-) untreated group (605 cases), according to the TPOAb result and acceptance the levothyroxine treatment. 2 000 pregnant women with normal thyroid function who delivered in the same period were selected as the control group. Perinatal outcomes were analyzed. Results (1) The incidence of SCH in early pregnancy was 13.61%(2 042/15 000). 60.53%(1 236/2 042) accepted levothyroxine treatment and 39.47%(806/2 042) did not. (2) The incidence of abortion (5.71%, 46/806), premature delivery (6.20%, 50/806), gestational hypertension disease (13.90%, 112/806), gestational diabetes mellitus (GDM;6.58%, 53/806), fetal growth restriction (FGR;12.28%, 99/806)and low birth weight infants (10.17%, 82/806)in the untreated group were higher than those in the treated group [3.96%(49/1 236), 4.21%(52/1 236), 10.76%(133/1 236), 4.13%(51/ 1 236), 8.90%(110/1 236), 7.52%(93/1 236), respectively] and the control group [3.60% (72/2 000), 4.00%(80/2 000) , 10.70%(214/2 000) , 3.80%(76/2 000), 9.60%(192/2 000), 7.50%(150/2 000), respectively]. The differences were statistically significant (P<0.05). While there was no statistically significant difference in the incidence of placental abruption, anemia in pregnant women, or fetal distress among the three groups (P>0.05). (3)The incidences of abortion (11.44%, 23/201), premature delivery (12.44%, 25/201), gestational hypertension disease (22.89%, 46/201), GDM (8.46%, 17/201), FGR (19.90%, 40/201) and low birth weight infants (16.42%, 33/201) in the TPOAb (+) untreated group were higher than those in TPOAb (+) treated group [4.02% (41/1 021), 4.21% (43/1 021), 10.77% (110/1 021), 4.11% (42/1 021), 8.72% (89/1 021), 7.35%(75/1 021), respectively] and the control group, with statistically significant differences (P<0.05). The incidence of the pregnancy complications in the TPOAb (+) treated group was higher than those in the control group, but the differences were not statistically significant (P>0.05). (4)There were no statistically significant difference (P> 0.05) in the incidence of abortion (3.72%, 8/215), premature delivery (4.19%, 9/215), gestational hypertension disease (10.70%, 23/215), GDM (4.19%, 9/215), FGR (9.77%, 21/215) or low birth weight infants (8.37%, 18/215) among the TPOAb (-) treated group, the TPOAb (-) untreated group [3.80% (23/605), 4.13%(25/605), 10.91%(66/605), 5.95%(36/605), 9.75%(59/605), 8.10%(49/605), respectively] and the control group. Conclusions (1) The incidence of abortion, premature delivery, gestational hypertension disease, GDM, FGR and low birth weight infants could be increased in women with SCH in early pregnancy.(2) Thyroxine treatment could reduce the incidence of pregnancy complications in women with SCH in early pregnancy. Objective To investigate if women with subclinical hypothyroidism (SCH), positive thyroid gland peroxidase antibody(TPOAb) in early pregnancy accepted treatment or not had effect on perinatal outcomes. Methods 15 000 pregnant women who delivered in Women and Infants Hospital of Zhengzhou from January 1, 2013 to June 30, 2014 were recruited retrospectively. Among them, 2 042 women had SCH in early pregnancy. The diagnostic standard of SCH was serum free thyroxine (FT4) between 12.91-22.35 pmol/L and TSH level between 5.22-10.00 mU/L. TPOAb level ≥34 U/L was defined as positive result. The 2 042 patients with SCH were divided into the treated group (1 236 cases) and the untreated group (806 cases), according to whether or not women accepted the levothyroxine treatment. Meanwhile, the 2 042 patients with SCH were divided into the TPOAb (+) treated group (1 021 cases), the TPOAb (+) untreated group (201 cases), the TPOAb (-) treated group (215 cases) and the TPOAb (-) untreated group (605 cases), according to the TPOAb result and acceptance the levothyroxine treatment. 2 000 pregnant women with normal thyroid function who delivered in the same period were selected as the control group. Perinatal outcomes were analyzed. Results (1) The incidence of SCH in early pregnancy was 13.61%(2 042/15 000). 60.53%(1 236/2 042) accepted levothyroxine treatment and 39.47%(806/2 042) did not. (2) The incidence of abortion (5.71%, 46/806), premature delivery (6.20%, 50/806), gestational hypertension disease (13.90%, 112/806), gestational diabetes mellitus (GDM;6.58%, 53/806), fetal growth restriction (FGR;12.28%, 99/806)and low birth weight infants (10.17%, 82/806)in the untreated group were higher than those in the treated group [3.96%(49/1 236), 4.21%(52/1 236), 10.76%(133/1 236), 4.13%(51/ 1 236), 8.90%(110/1 236), 7.52%(93/1 236), respectively] and the control group [3.60% (72/2 000), 4.00%(80/2 000) , 10.70%(214/2 000) , 3.80%(76/2 000), 9.60%(192/2 000), 7.50%(150/2 000), respectively]. The differences were statistically significant (P<0.05). While there was no statistically significant difference in the incidence of placental abruption, anemia in pregnant women, or fetal distress among the three groups (P>0.05). (3)The incidences of abortion (11.44%, 23/201), premature delivery (12.44%, 25/201), gestational hypertension disease (22.89%, 46/201), GDM (8.46%, 17/201), FGR (19.90%, 40/201) and low birth weight infants (16.42%, 33/201) in the TPOAb (+) untreated group were higher than those in TPOAb (+) treated group [4.02% (41/1 021), 4.21% (43/1 021), 10.77% (110/1 021), 4.11% (42/1 021), 8.72% (89/1 021), 7.35%(75/1 021), respectively] and the control group, with statistically significant differences (P<0.05). The incidence of the pregnancy complications in the TPOAb (+) treated group was higher than those in the control group, but the differences were not statistically significant (P>0.05). (4)There were no statistically significant difference (P> 0.05) in the incidence of abortion (3.72%, 8/215), premature delivery (4.19%, 9/215), gestational hypertension disease (10.70%, 23/215), GDM (4.19%, 9/215), FGR (9.77%, 21/215) or low birth weight infants (8.37%, 18/215) among the TPOAb (-) treated group, the TPOAb (-) untreated group [3.80% (23/605), 4.13%(25/605), 10.91%(66/605), 5.95%(36/605), 9.75%(59/605), 8.10%(49/605), respectively] and the control group. Conclusions (1) The incidence of abortion, premature delivery, gestational hypertension disease, GDM, FGR and low birth weight infants could be increased in women with SCH in early pregnancy.(2) Thyroxine treatment could reduce the incidence of pregnancy complications in women with SCH in early pregnancy.